Drug intelligence / Profile preview

GBV-006

Development stage: Preclinical
Lead developer: Globavir Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**GBV-006** is an investigational, orally administered combination of two repurposed small-molecule drugs developed from research at Stanford University and licensed worldwide to Globavir. It was described as a host-directed broad-spectrum antiviral combination intended to interfere with host-cell vesicular-trafficking machinery needed for viral entry, assembly, and egress. Globavir evaluated the program preclinically for dengue and other viral illnesses and partnered with the SingHealth Duke-NUS Academic Medical Centre to support research and potential clinical evaluation in dengue and chikungunya; the individual active ingredients and their molecular targets have not been publicly disclosed.

Other names: GBV 006GBV006GBV-006

Beyond the preview

Go deeper on GBV-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBV-006.

Explore the full profile